Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 8, 1996, Pages 2776-2782

  Copinschi, Georges ^a,e   Van Onderbergen, Anne ^a   L'Hermite Balériaux, Mireille ^a   Mendel, Carl M ^d   Caufriez, Anne ^a   Leproult, Rachel ^b   Bolognese, James A ^d   De Smet, Marina ^d   Thorner, Michael O ^c   Van Cauter, Eve ^b  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e School of Medicine   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING PEPTIDE; HYDROCORTISONE; IBUTAMOREN; PRASTERONE SULFATE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADRENAL CORTEX FUNCTION; ADULT; AGING; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER;

ADMINISTRATION, ORAL; ADOLESCENT; ADRENAL CORTEX; ADULT; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; GROWTH HORMONE; HUMANS; INDOLES; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; REFERENCE VALUES; SLEEP STAGES; SPIRO COMPOUNDS;

EID: 10144227766     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.8.2776     Document Type: Article

References (43)

1. Thorner M, Vance M, Horvath E, Kovacs K. 1991 The anterior pituitary. In: Wilson JD, Foster DW, eds. Williams' textbook of endocrinology. Philadelphia: Saunders; 221-310.
2. Tannenbaum GS, Ling N. 1984 The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology. 115:1952-1957.
3. Bowers CY. 1994 On a peptidomimetic growth hormone-releasing peptide [Editorial]. J Clin Endocrinol Metab. 79:940-942.
4. Goth M, Lyons C, Canny B, Thorner M. 1992 Pituitary adenylate cyclase activating polypeptide, GH-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors. Endocrinology. 130:939-944.
5. Bowers C, Sartor A, Reynolds G, Badger T. 1991 On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology. 128:2027-2035.
6. Cheng K, Chan WWS, Barretto Jr A, Convey E, Smith R. 1989 The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3′,5′-monophosphate accumulation in rat pituitary cell culture. Endocrinology. 124:2791-2798.
7. Blake A, Smith R. 1991 Desensitization studies using perifused rat pituitary cells show that growth hormone-releasing hormone and His-D-Trp-Ala-TRP-D-Phe-Lys-NH2 stimulate growth hormone release through distinct receptor sites. J Endocrinol. 129:11-19.
8. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. 1990 Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 70:975-982.
9. Huhn WC, Hartmann ML, Pezzoli SS, Thorner MO. 1993 Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion, and specifically attenuates the response to a subsequent GHRP bolus. J Clin Endocrinol Metab. 76:1202-1208.
10. Jaffe C, Ho P, Demott-Friberg R, Bowers C, Barkan A. 1993 Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. J Clin Endocrinol Metab. 77:1641-1647.
11. Bowers C, Momany F, Reynolds G, Hong A. 1984 On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 114:1537-1545.
12. Ilson B, Jorkasky D, Curnow R, Stote R. 1989 Effects of a new hexapeptide to selectively stimulate growth hormone release in healthy human subjects. J Clin Endocrinol Metab. 69:212-214.
13. 2 (growth hormone releasing peptide) increased plama growth hormone and insulin-like growth factor-I levels in normal men. Endocrinol Jpn. 38:15-21.
14. Smith R, Cheng K, Schoen W, et al. 1993 A nonpeptidyl growth hormone secretagogue. Science. 260:1640-1643.
15. Cheng K, Chan WWS, Butler B, et al. 1993 Stimulation of growth hormone release from rat primary pituitary cells by E-692,429, a novel non-peptidyl GH secretagogue. Endocrinology. 132:2729-2731.
16. Gertz B, Barrett J, Eisenhandler R, et al. 1993 Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6. J Clin Endocrinol Metab. 77:1393-1397.
17. Patchett AA, Nargund RP, Tata JR, et al. 1995 Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci USA. 92:7001-7005.
18. Mendel C. 1989 The free hormone hypothesis: a physiologically based mathematical model. Endocr Rev. 10:232-274.
19. Dunn J, Nisula B, Rodbard D. 1981 Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and cortico-steroid-binding globulin in human plasma. J Clin Endocrinol Metab. 53:58-68.
20. Rechtschaffen A, Kales A. 1968 A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Washington DC: US Government Printing Office.
21. Van Cauter E. 1981 Quantitative methods for the analysis of circadian and episodic hormone fluctuations. In: Van Cauter E, Copinschi G, eds. Human pituitary hormones: circadian and episodic variations. Martinus Nyhoff: The Hague; 1-25.
22. Van Cauter E. 1988 Estimating false-positive and false-negative errors in analyses of hormonal pulsatility. Am J Physiol. 254:E786-E794.
23. Van Cauter E, Kerkhofs M, Caufriez A, Van Onderbergen A, Thorner MO, Copinschi G. 1992 A quantitative estimation of GH secretion in normal man: reproducibility and relation to sleep and time of day. J Clin Endocrinol Metab. 74:1441-1450.
24. Cleveland WS. 1979 Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc. 74:829-836.
25. Van Cauter E. 1990 Computer-assisted analysis of endocrine rhythms. In: Rodbard D, Forti G, eds. Computers in endocrinology. Raven Press: New York; 59-70.
26. Van Cauter E, Shapiro ET, Tillil H, Polonsky KS. 1992 Circadian modulation of glucose and insulin responses to meals: relationship to Cortisol rhythm. Am J Physiol. 262:E467-E475.
27. Bradley EM, Waterhouse C. 1966 Effect of estrogen administration on extravascular Cortisol. J Clin Endocrinol Metab. 26:705-714.
28. van Coevorden A, Mockel J, Laurent E, et al. 1991 Nouroendocrine rhythms and sleep in aging. Am J Physiol. 260:E651-E661.
29. Cuneo R, Salomon F, McGauley G, Sonksen P. 1992 The growth hormone deficiency syndrome in adults. Clin Endocrinol (Oxf). 37:387-397.
30. Rosen T, Hansson T, Granhed H, Szucs J, Bengtsson B. 1993 Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol (Coponh). 129:201-206.
31. Marcus R, Butterfield G, Holloway L, et al. 1990 Effects of short term administration of recombinant human growth hormone to elderly people. J Clin Endocrinol Metab. 70:519-527.
32. Rudman D, Feller AG, Nagraj HS, et al. 1990 Effects of human growth hormone in men over 60 years old. N Engl J Med. 323:1-6.
33. Rudman D, Feller AG, Cohn L, Shetty KR, Rudman IW, Draper MW. 1991 Effects of human growth hormone on body composition in elderly men. Horm Res. 36(Suppl I):73-81.
34. Aloi JA, Gertz BJ, Hartman ML, et al. 1994 Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects. J Clin Endocrinol Metab. 79:943-949.
35. Faria ACS, Veldhuis JD, Thorner MO, Vance ML. 1989 Half-time of endogenous growth hormone (GH) disappearance in normal man after stimulation of GH secretion by GH-releasing hormone, and suppression with somatostatin. J Clin Endocrinol Metab. 68:535-541.
36. Guler H, Zapf J, Schmid C, Froesch E. 1989 Insulin-like growth factors I, and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol (Copenh). 121:753-758.
37. Arvat E, Gianotti L, Grottoli S, et al. Effects of short-term intranasal or oral tratment with hexarelin, a synthetic hexapeptide, on the GH-IGF-1 axis in human aging [Abstract]. Proc of the 77th Annual Meet of The Endocrine Soc. 1195;507.
38. Breier B, Milsom S, Blum W, Schwander J, Gallaher B, Gluckman P. 1993 Insulin-like growth factors, and their binding proteins in plasma and milk after growth hormone-stimulated galactopoiesis in normally lactating women. Acta Endocrinol (Copenh). 129:427-435.
39. Valk N, Van de Lely A, De Herder W, Lindemans J, Lamberts S. 1994 The effects of human growth hormone (GH) administration in GH-deficient adults: a 20-day metabolic ward study. J Clin Endocrinol Metab. 79:1070-1076.
40. Baulieu E, Corpechot C, Dray F, et al. 1965 An adrenal-secreted "androgen:" dehydroepiandrosterone sulfate. Its metabolism and a tentative generalization on the metabolism of other steroid conjugates in man. Recent Prog Horm Res. 21:411-494.
41. Morales AJ, Nolan JJ, Nelson JC, Yen SSC. 1994 Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab. 78:1360-1367.
42. Rudman D, Kutner MH, Rogers M, Lubin MF, Fleming GA, Bain FP. 1981 Impaired growth hormone secretion in the adult population. J Clin Invest. 67:1361-1369.
43. Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, et al. 1994 Serum insulin-like growth factor 1 in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol (Oxf). 41:351-357.